<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Acta Orthop</journal-id>
      <journal-id journal-id-type="iso-abbrev">Acta Orthop</journal-id>
      <journal-id journal-id-type="publisher-id">ORT</journal-id>
      <journal-title-group>
        <journal-title>Acta Orthopaedica</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1745-3674</issn>
      <issn pub-type="epub">1745-3682</issn>
      <publisher>
        <publisher-name>Informa Healthcare</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">22998530</article-id>
      <article-id pub-id-type="pmc">3488185</article-id>
      <article-id pub-id-type="doi">10.3109/17453674.2012.729183</article-id>
      <article-id pub-id-type="publisher-id">ORT_A_729183_O</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Atypical femoral fracture following bisphosphonate treatment in a woman with osteogenesis imperfecta&#x2014;a case report</article-title>
      </title-group>
      <contrib-group>
        <contrib id="a1" contrib-type="author" corresp="no">
          <name>
            <surname>Meier</surname>
            <given-names>Raphael P H</given-names>
          </name>
          <xref ref-type="aff" rid="AF0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="a2" contrib-type="author" corresp="no">
          <name>
            <surname>Lorenzini</surname>
            <given-names>Kuntheavy Ing</given-names>
          </name>
          <xref ref-type="aff" rid="AF0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="a3" contrib-type="author" corresp="no">
          <name>
            <surname>Uebelhart</surname>
            <given-names>Brigitte</given-names>
          </name>
          <xref ref-type="aff" rid="AF0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="a4" contrib-type="author" corresp="no">
          <name>
            <surname>Stern</surname>
            <given-names>Richard</given-names>
          </name>
          <xref ref-type="aff" rid="AF0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="a5" contrib-type="author" corresp="no">
          <name>
            <surname>Peter</surname>
            <given-names>Robin E</given-names>
          </name>
          <xref ref-type="aff" rid="AF0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="a6" contrib-type="author" corresp="no">
          <name>
            <surname>Rizzoli</surname>
            <given-names>Ren&#xE9;</given-names>
          </name>
          <xref ref-type="aff" rid="AF0003">
<sup>3</sup>
</xref>
        </contrib>
        <aff id="AF0001">
          <sup>1</sup>
          <institution>Department of Surgery</institution>
        </aff>
        <aff id="AF0002">
          <sup>2</sup>
          <institution>Division of Clinical Pharmacology and Toxicology</institution>
        </aff>
        <aff id="AF0003"><sup>3</sup><institution>Division of Bone Diseases, Department of Medical Specialties</institution>,</aff>
        <aff id="AF0004"><sup>4</sup><institution>Division of Orthopedic Surgery, Department of Surgery, University Hospitals of Geneva, and Faculty of Medicine</institution>, <addr-line>Geneva</addr-line>, <country>Switzerland</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1">Correspondence: <email xlink:href="Rene.Rizzoli@unige.ch">Rene.Rizzoli@unige.ch</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>10</month>
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>22</day>
        <month>10</month>
        <year>2012</year>
      </pub-date>
      <volume>83</volume>
      <issue>5</issue>
      <fpage>548</fpage>
      <lpage>550</lpage>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>2</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>6</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright: &#xA9; Nordic Orthopaedic Federation</copyright-statement>
        <copyright-year>2012</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the source is credited.</license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <p>A 75-year-old woman presented with acute pain and deformity of her right lower extremity after a fall from standing height. She had suffered from diffuse pain in the right thigh for 4 months, which had begun after some physical exercise with no trauma. Radiographs revealed an atypical fracture of the right femoral shaft, short oblique, with thickening of the entire lateral cortex (9.3 mm as compared to 7.2 mm at the same level on the contralateral nailed femur) and localized cortical reaction at the level of the fracture (<xref ref-type="fig" rid="F1">Figure</xref>).</p>
    <fig fig-type="figure" id="F1" orientation="portrait" position="float">
      <label>Figure.</label>
      <caption>
        <p>The atypical fracture of the right femur.</p>
      </caption>
      <graphic xlink:href="ORT-1745-3674-083-548_g001"/>
    </fig>
    <p>The patient had been diagnosed in childhood with a familial form of osteogenesis imperfecta caused by a de novo mutation. Her parents and siblings had no evidence of bone fragility, but 5 of her 6 children had had multiple fractures starting in childhood, associated with typical clinical signs of type-I collagen abnormalities (<xref ref-type="bibr" rid="CIT0014">Rauch and Glorieux 2004</xref>).</p>
    <p>Since childhood, our patient had sustained at least 35 fractures, all of which had healed within a normal period of time. The first to be documented was a femoral fracture at the age of 2, followed by many others involving tibia, radius, ulna, humerus, fingers and toes, bilaterally, until the age of 12. From 12 to 27 years of age there were no fractures reported. At the age of 27 the patient had sustained a wrist fracture, and at the age of 35 she had presented with multiple vertebral compression fractures after falling from a tree. More recent events included a high-energy left midshaft femoral fracture during sports at the age of 62, followed by a fracture of the great toe when she was 71.</p>
    <p>Because of multiple fractures and osteoporosis (the femoral neck T-score dropped to &#x2013;2.8 standard deviation when she was 72), she had been administered alendronate (70 mg/week) for the following 3 years, together with calcium and vitamin D supplements (Calcimagon-D3 2 tablets/day). Prior to that, she had been on estrogen replacement therapy (Estraderm day patch) for 13 years. Efficacy of treatment was determined by repeated densitometric evaluations and bone resorption level measurements; the deoxypyridinoline/creatinine ratio was 11 when she was 68 years old, 17 at the age of 72, and 12 one year later (normal range: 8&#x2013;20).</p>
    <p>The patient&#x2019;s femoral fracture was stabilized with an intramedullary nail. Her postoperative course was uneventful and she was discharged 12 days after surgery. At 1-year follow-up, the fracture was well healed. Alendronate was discontinued a few weeks after the atypical fracture.</p>
    <sec sec-type="discussion" id="ss1">
      <title>Discussion</title>
      <p>To the best of our knowledge, this is the first reported case of an atypical femoral fracture in a patient with osteogenesis imperfecta who has been treated with bisphosphonates. The clinical and radiographic presentation is compatible with all 5 major features described by the American Society for Bone and Mineral Research (ASBMR) task force, and 4 of the minor features also (<xref ref-type="bibr" rid="CIT0020">Shane et al. 2010</xref>). In particular, the fracture was preceded by thigh pain. Despite the high number of recurrent fractures, the femur was involved only once prior to this most recent episode, but this involved the contralateral femur and was a result of high-energy trauma. The patient started on alendronate therapy and a good response was observed with an increase in bone mineral density of the lumbar spine and femoral neck. In addition, the indices of bone resorption decreased over the same time period. While no typical osteoporotic fractures had occurred since initiation of bisphosphonate, the patient developed an atypical femoral fracture after 3 years of treatment. It is therefore conceivable that the reduction in bone turnover together with the increase in bone stiffness may have avoided typical osteoporotic fractures while favoring the accumulation of microdamage at the point of maximal stress (<xref ref-type="bibr" rid="CIT0012">Pauwels 1948</xref>), thus contributing to the development of an insufficiency fracture (<xref ref-type="bibr" rid="CIT0009">Mashiba et al. 2001</xref>, <xref ref-type="bibr" rid="CIT0010">2005</xref>).</p>
      <p>Nevertheless, the most obvious factor that could have contributed to the occurrence of this stress fracture is the osteogenesis imperfecta itself, and this has been reported (<xref ref-type="bibr" rid="CIT0019">Shabat 2000</xref>). On the other hand, although partially improved with bisphosphonate treatment, the osteoporosis could have been responsible&#x2014;as it may contribute to fractures in adults with osteogenesis imperfecta (<xref ref-type="bibr" rid="CIT0003">Bornemann et al. 1987</xref>). In addition, there may be some phenotypic and genotypic overlap between mild osteogenesis imperfecta and postmenopausal osteoporosis (<xref ref-type="bibr" rid="CIT0021">Spotila et al. 1991</xref>).</p>
      <p>Another possible explanation would be a negative interaction between all three factors: a type-I collagen abnormality, osteoporosis, and bisphosphonate. The latter possibly alters collagen maturity and crosslinking in newly formed bone (<xref ref-type="bibr" rid="CIT0005">Durchschlag et al. 2006</xref>). However, bisphosphonates have been used successfully in the treatment of osteogenesis imperfecta in children and in young adults (<xref ref-type="bibr" rid="CIT0013">Phillipi et al. 2008</xref>), resulting in a 14&#x2013;31% decrease in the rate of fracture, an increase in height, reduced bone pain, and better quality of life (<xref ref-type="bibr" rid="CIT0002">Adami et al. 2003</xref>, <xref ref-type="bibr" rid="CIT0016">Sakkers et al. 2004</xref>, <xref ref-type="bibr" rid="CIT0006">Gatti et al. 2005</xref>, <xref ref-type="bibr" rid="CIT0008">Letocha et al. 2005</xref>, <xref ref-type="bibr" rid="CIT0018">Seikaly et al. 2005</xref>, <xref ref-type="bibr" rid="CIT0004">DiMeglio and Peacock 2006</xref>). These observations have not been confirmed in older patients, probably due to the low prevalence of osteogenesis imperfecta in adults, which is reported to be 31 cases per 10<sup>6 </sup>individuals (<xref ref-type="bibr" rid="CIT0024">Wekre et al. 2010</xref>).</p>
      <p>While atypical femoral fractures have mainly been reported in patients taking bisphosphonates (<xref ref-type="bibr" rid="CIT0017">Schilcher et al. 2011</xref>, <xref ref-type="bibr" rid="CIT0011">Meier et al. 2012</xref>), certainly not all the patients who are treated this way develop these stress fractures. One or more co-factors may be involved, leading to enhanced susceptibility to atypical femoral fractures. These might include co-medication, previous underlying disease affecting bone integrity, proton-pump inhibitors and corticosteroids (<xref ref-type="bibr" rid="CIT0007">Ing-Lorenzini et al. 2009</xref>, <xref ref-type="bibr" rid="CIT0015">Rizzoli et al. 2011</xref>), possible negative pharmacodynamic interactions with other antiresorptive drugs such as estrogen, raloxifene, calcitonin, or denosumab (<xref ref-type="bibr" rid="CIT0023">Visekruna et al. 2008</xref>, <xref ref-type="bibr" rid="CIT0020">Shane et al. 2010</xref>), or the presence of an underlying disease affecting bone integrity such as rheumatoid arthritis, diabetes, cancer, hypophosphatasia, or vitamin D deficiency.</p>
      <p>Recently, <xref ref-type="bibr" rid="CIT0017">Schilcher et al. (2011)</xref> published detailed information about co-medication in patients with an atypical fracture (e.g. hormone replacement therapy, corticosteroids, proton-pump inhibitors), and they observed no difference from patients with ordinary subtrochanteric fractures. In addition, there were no co-morbidities associated with atypical fractures. More specifically, some authors have searched for other potential risk factors in bisphosphonate-free patients with atypical femoral fractures, but so far without success (<xref ref-type="bibr" rid="CIT0022">Tan et al. 2011</xref>).</p>
      <p>This case report is the first to document that atypical femoral fractures can occur in patients with osteogenesis imperfecta, irrespective of whether or not this is related to treatment with bisphosphonates. Further investigation of a possible synergistic relationship between atypical fractures associated with bisphosphonate use and osteogenesis imperfecta may provide new information about the pathological mechanisms implicated in atypical femoral fractures.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>RM: case study, research, and writing of the manuscript. KI, BU, RS, RP, and RR: supervision and review of the manuscript.</p>
    </ack>
    <ref-list>
      <ref id="CIT0001">
        <element-citation publication-type="other">
          <person-group person-group-type="author">
            <collab>Funds were recieved from University Hospitals of Geneva</collab>
          </person-group>
        </element-citation>
      </ref>
      <ref id="CIT0002">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adami</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gatti</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Colapietro</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Intravenous neridronate in adults with osteogenesis imperfecta</article-title>
          <source>J Bone Miner Res</source>
          <year>2003</year>
          <volume>18</volume>
          <issue>1</issue>
          <fpage>126</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">12510813</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0003">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bornemann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saxon</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Kidd</surname>
              <given-names>GS</given-names>
              <suffix>2nd</suffix>
            </name>
          </person-group>
          <article-title>Osteoporosis unmasked by hyperthyroidism in a young man with osteogenesis imperfecta</article-title>
          <source>Arch Intern Med</source>
          <year>1987</year>
          <volume>147</volume>
          <issue>11</issue>
          <fpage>1947</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">3675095</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0004">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>DiMeglio</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Peacock</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta</article-title>
          <source>J Bone Miner Res</source>
          <year>2006</year>
          <volume>21</volume>
          <issue>1</issue>
          <fpage>132</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">16355282</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0005">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Durchschlag</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Paschalis</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Zoehrer</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate</article-title>
          <source>Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research</source>
          <year>2006</year>
          <volume>21</volume>
          <issue>10</issue>
          <fpage>1581</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="pmid">16995813</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0006">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gatti</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Antoniazzi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Prizzi</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study</article-title>
          <source>J Bone Miner Res</source>
          <year>2005</year>
          <volume>20</volume>
          <issue>5</issue>
          <fpage>758</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="pmid">15824848</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0007">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ing-Lorenzini</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Desmeules</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Plachta</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital</article-title>
          <source>Drug Saf</source>
          <year>2009</year>
          <volume>32</volume>
          <issue>9</issue>
          <fpage>775</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">19670917</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0008">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Letocha</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Cintas</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Troendle</surname>
              <given-names>JF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement</article-title>
          <source>J Bone Miner Res</source>
          <year>2005</year>
          <volume>20</volume>
          <issue>6</issue>
          <fpage>977</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="pmid">15883638</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0009">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mashiba</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Turner</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Hirano</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles</article-title>
          <source>Bone</source>
          <year>2001</year>
          <volume>28</volume>
          <issue>5</issue>
          <fpage>524</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">11344052</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0010">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mashiba</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Burr</surname>
              <given-names>DB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib</article-title>
          <source>J Bone Miner Metab</source>
          <year>2005</year>
          <volume>23</volume>
          <issue>(Suppl)</issue>
          <fpage>36</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">15984412</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0011">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meier</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Perneger</surname>
              <given-names>TV</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Increasing occurrence of atypical femoral fractures associated with bisphosphonate use</article-title>
          <source>Arch Intern Med</source>
          <year>2012</year>
          <volume>172</volume>
          <issue>12</issue>
          <fpage>930</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">22732749</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0012">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pauwels</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Die Bedeutung der Bauprinzipien des Stutz-und Bewegungsapparates fur die Beanspruchung der R&#xF6;hrenknochen</article-title>
          <source>Z Anat Entwicklungsgesch</source>
          <year>1948</year>
          <volume>114</volume>
          <issue>1-2</issue>
          <fpage>129</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="pmid">18884220</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0013">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Phillipi</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Remmington</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Steiner</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
          <article-title>Bisphosphonate therapy for osteogenesis imperfecta</article-title>
          <source>Cochrane Database Syst Rev</source>
          <year>2008</year>
          <issue>4</issue>
          <fpage>CD005088</fpage>
          <pub-id pub-id-type="pmid">18843680</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0014">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rauch</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Glorieux</surname>
              <given-names>FH</given-names>
            </name>
          </person-group>
          <article-title>Osteogenesis imperfecta</article-title>
          <source>Lancet</source>
          <year>2004</year>
          <volume>363</volume>
          <issue>9418</issue>
          <fpage>1377</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">15110498</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0015">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rizzoli</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Akesson</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bouxsein</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report</article-title>
          <source>Osteoporos Int</source>
          <year>2011</year>
          <volume>22</volume>
          <issue>2</issue>
          <fpage>373</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="pmid">21085935</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0016">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sakkers</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kok</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Engelbert</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study</article-title>
          <source>Lancet</source>
          <year>2004</year>
          <volume>363</volume>
          <issue>9419</issue>
          <fpage>1427</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">15121405</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0017">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schilcher</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Michaelsson</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Aspenberg</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Bisphosphonate use and atypical fractures of the femoral shaft</article-title>
          <source>N Engl J Med</source>
          <year>2011</year>
          <volume>364</volume>
          <issue>18</issue>
          <fpage>1728</fpage>
          <lpage>37</lpage>
          <pub-id pub-id-type="pmid">21542743</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0018">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seikaly</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Kopanati</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Salhab</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Impact of alendronate on quality of life in children with osteogenesis imperfecta</article-title>
          <source>J Pediatr Orthop</source>
          <year>2005</year>
          <volume>25</volume>
          <issue>6</issue>
          <fpage>786</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="pmid">16294137</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0019">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shabat</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Osteogenesis imperfecta-induced migratory stress fractures in a military recruit</article-title>
          <source>Clin Exp Rheumatol</source>
          <year>2000</year>
          <volume>18</volume>
          <issue>5</issue>
          <fpage>654</fpage>
          <pub-id pub-id-type="pmid">11072619</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0020">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shane</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Burr</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ebeling</surname>
              <given-names>PR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research</article-title>
          <source>J Bone Miner Res</source>
          <year>2010</year>
          <volume>25</volume>
          <issue>11</issue>
          <fpage>2267</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="pmid">20842676</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0021">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spotila</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Constantinou</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Sereda</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutation in a gene for type I procollagen (COL1A2) in a woman with postmenopausal osteoporosis: evidence for phenotypic and genotypic overlap with mild osteogenesis imperfecta</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>1991</year>
          <volume>88</volume>
          <issue>12</issue>
          <fpage>5423</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">2052622</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0022">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tan</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Koh</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Goh</surname>
              <given-names>SK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Atypical femoral stress fractures in bisphosphonate-free patients</article-title>
          <source>Osteoporos Int</source>
          <year>2011</year>
          <volume>22</volume>
          <issue>7</issue>
          <fpage>2211</fpage>
          <lpage>2</lpage>
          <pub-id pub-id-type="pmid">20838769</pub-id>
        </element-citation>
      </ref>
      <ref id="CIT0023">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Visekruna</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>McKiernan</surname>
              <given-names>FE</given-names>
            </name>
          </person-group>
          <article-title>Severely suppressed bone turnover and atypical skeletal fragility</article-title>
          <source>J Clin Endocrinol Metsb</source>
          <year>2008</year>
          <volume>93</volume>
          <issue>8</issue>
          <fpage>2948</fpage>
          <lpage>52</lpage>
        </element-citation>
      </ref>
      <ref id="CIT0024">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wekre</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Froslie</surname>
              <given-names>KF</given-names>
            </name>
            <name>
              <surname>Haugen</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A population-based study of demographical variables and ability to perform activities of daily living in adults with osteogenesis imperfecta</article-title>
          <source>Disabil Rehabil</source>
          <year>2010</year>
          <volume>32</volume>
          <issue>7</issue>
          <fpage>579</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="pmid">20136476</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
